Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH505TF gp120
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CH505TF gp120 is a recombinant HIV-1 envelope (Env) glycoprotein subunit vaccine candidate, specifically the "transmitted/founder" (TF) form of the clade C HIV-1 Env protein, known as gp120. It is designed to induce immune responses—particularly precursors for broadly neutralizing antibodies (bnAbs)—against HIV. The protein is produced via recombinant DNA technology in mammalian cell lines using either stable or transient transfection methods, with both approaches shown to yield equivalent safety and immunogenicity profiles in clinical trials. The vaccine has been evaluated primarily in combination with the adjuvant GLA-SE (glucopyranosyl lipid A-stable emulsion), aiming to enhance immunogenicity. Its main indication is prevention of HIV infection, especially in infants born to mothers living with HIV[2][6][7][8][10].
- Other names
- HIV-1 Env protein CH505 transmitted/founder gp120CH505 transmitter-founder gp120CH-505 transmitter-founder gp120CH 505 transmitter-founder gp120
02
Targets
Env (HIV-1 envelope glycoprotein)gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on CH505TF gp120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH505TF gp120.